机构:[1]Department of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China[2]Department of Paediatrics, Beijing Children’s Hospital, Capital Medical University, Xicheng District, Beijing, China临床科室新生儿中心首都医科大学附属北京儿童医院[3]Department of Endocrinology, Beijing Key Lab of TCM Collateral Disease theory Research, Fengtai District, Beijing, China
Background: Endoplasmic reticulum stress is associated with podocyte apoptosis in the pathogenesis of diabetic nephropathy (DN). A previous study has demonstrated that emodin has a protective effect in the kidney by suppressing proliferation of mesangial cells and inhibiting the renal tubular epithelial-to-mesenchymal transition. However, the effects of emodin on the podocyte apoptosis in DN and its mechanisms are unknown. Aim: This study aimed to explore the effect of emodin on DN model KK-Ay mice and high glucose induced podocytes apoptosis via the PERK-eIF2 alpha pathway. Methods: KK-Ay mice model of DN were treated with emodin at dose of 40 and 80 mg/kg/day for 8 weeks. Urine albumin, serum creatinine, blood urea nitrogen levels and the renal histopathology in mice were performed. In vitro, conditionally immortalized mouse podocytes exposed to FIG (30mM) were incubated with emodin. Cell viability was measured by CCK-8 assay. Additionally, we performed RNA interference and measured the apoptosis in cultured podocytes treated with emodin. Immunohistochemistry, immunofluorescence, western blot, and real-time PCR were used to detect gene and protein expression both in vivo and in vitro. Results: The results showed that emodin treatment ameliorated urine albumin, serum creatinine, and blood urea nitrogen of DN mice. The pathological damage of kidney tissue was also improved after treatment with emodin. Moreover, emodin increased nephrin expression. Podocytes apoptosis and endoplasmic reticulum stress markers (GRP78) were significantly reduced upon emodin treatment. Furthermore, emodin treatment decreased the expression of phosphorylated protein kinase RNA-like endoplasmic reticulum kinase (P-PERK), phosphorylated P-eIF2 alpha, ATF4, and CHOP. In vitro, emodin treatment was further found to decrease the GRP78 level induced by high glucose or tunicamycin (TM). Besides, emodin and PERK knockdown inhibited the apoptosis of podocytes cultured in high glucose by counteracting the upregulation of phosphorylated PERK, phosphorylated eIF2 alpha, ATF4, and CHOP. Conclusion: Overall, the findings indicate that emodin mitigates podocytes apoptosis by inhibiting the PERK-eIF2 alpha signaling pathway in vivo and in vitro, and, therefore, exerts a protective action on podocytes in DN.
基金:
Scientific Research Project of Beijing Educational Committee [KZ201610025024]; Major National Basic Research Program of China (973 Program)National Basic Research Program of China [2012CB518602]
第一作者机构:[1]Department of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China
通讯作者:
通讯机构:[1]Department of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China[*1]Department of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, 10 Youanmenwai, Xitoutiao, Fengtai District, Beijing 100069, China
推荐引用方式(GB/T 7714):
Tian Nianxiu,Gao Yanbin,Wang Xiaolei,et al.Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy[J].DRUG DESIGN DEVELOPMENT AND THERAPY.2018,12:2195-2211.doi:10.2147/DDDT.S167405.
APA:
Tian, Nianxiu,Gao, Yanbin,Wang, Xiaolei,Wu, Xiaoming,Zou, Dawei...&Shi, Yimin.(2018).Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy.DRUG DESIGN DEVELOPMENT AND THERAPY,12,
MLA:
Tian, Nianxiu,et al."Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy".DRUG DESIGN DEVELOPMENT AND THERAPY 12.(2018):2195-2211